Rituximab-induced Interstitial Pneumonitis in a Young Patient: A Case Report and Review of the Literature
Korean Journal of Hematology
;
: 423-427, 2007.
Artigo
em Inglês
| WPRIM
| ID: wpr-720983
ABSTRACT
Side effects of rituximab are mild in most cases, but there have been a few cases of severe pulmonary toxicity reported in elderly patients. Here we report a case of interstitial pneumonitis following rituximab treatment in a young patient. A 35-year-old woman with diffuse large B-cell lymphoma was admitted complaining of dry cough and dyspnea without fever after the 3 treatments with rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) chemotherapy. Her chest CT with high-resolution CT scanning confirmed the presence of bilateral diffuse ground-glass opacities. The analysis of arterial blood gases indicated hypoxemia. The pulmonary function testing showed a restrictive pattern. There were no other findings suggesting an infection. The findings were compatible with a rituximab-induced interstitial pneumonitis. After the patient was treated with prednisolone, the symptoms resolved. Cases with rituximab-induced interstitial pneumonitis develop principally in elderly patients. However, the condition also can occur in young patients.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Testes de Função Respiratória
/
Vincristina
/
Prednisolona
/
Doxorrubicina
/
Tomografia Computadorizada por Raios X
/
Linfoma de Células B
/
Doenças Pulmonares Intersticiais
/
Tosse
/
Tratamento Farmacológico
/
Dispneia
Limite:
Adulto
/
Idoso
/
Feminino
/
Humanos
Idioma:
Inglês
Revista:
Korean Journal of Hematology
Ano de publicação:
2007
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS